, Volume 13, Issue 5, pp 995-1002
Date: 17 Sep 2010

Preclinical Imaging of Therapy Response Using Metabolic and Apoptosis Molecular Imaging

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access



Early after therapy, 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) imaging is not always reliable due to the influx of inflammatory cells while apoptosis imaging offers a direct and early measurement of therapy effects. This study uses an improved apoptosis probe (99mTc-hAnxA5) in combination with [18F]FDG imaging to evaluate therapy response.


Daudi tumor tissue was implanted in the spleen of SCID mice. Treatment was performed with adriamycin and cyclophosphamide. Sequential [18F]FDG-positron emission tomography (PET) was acquired over 6 days and 99mTc-hAnxA5-SPECT was performed before and 1 day after therapy.


On day 1, therapy induced apoptosis was visualized with 99mTc-hAnxA5 without a measurable change in [18F]FDG uptake. [18F]FDG uptake decreased significantly on day 3 and was even more pronounced on day 6.


In this preclinical model, 99mTc-hAnxA5 imaging was able to detect apoptosis before metabolic changes were measured. These results confirm the value of apoptosis imaging for therapy response and give more insight in [18F]FDG imaging and its parameters to evaluate response.